Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum
Brief Summary: Patients with extensive and bulky disease are often those whose initial surgery is delayed after 3 or 4 cycles of neo-adjuvant chemotherapy.

In that case, there is, indeed, some concern to administer bevacizumab during the chemotherapy surrounding the interval debulking surgery due to the long half life (14- 21 days) of this monoclonal antibody and the interference of anti angiogenic agents with wound healing.

Vargatef® (Nintedanib) might offer a better alternative to bevacizumab in the neo-adjuvant setting. Vargatef® (Nintedanib) has a much shorter half-life of 7 to 19 hours. Preliminary experience in cancer did not show a trend for increased incidence of fistula or bowel perforation. For more details please refer to the investigator drug brochure for Vargatef® (Nintedanib).

This trial will compare progression-free survival and surgical complications of 188 patients with FIGO stage IIIC/IV treated in first line with either neo-adjuvant chemotherapy (carboplatin \& paclitaxel) and interval debulking surgery or the same treatment + Vargatef® (Nintedanib).


Options:
A: Arm Label: Olaratumab and Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Arm Label: Liposomal Doxorubicin: Optional Olaratumab Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Intervention Type: BIOLOGICAL; Name: Olaratumab; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin
B: Arm Label: vargatef/Nintedanib; Type: EXPERIMENTAL; Interventions: Drug: vargatef | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vargatef; Assigned to Arm(s): vargatef/Nintedanib | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: Arm I (PLD, atezolizumab); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm II (PLD, bevacizumab, atezolizumab); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Biological: Bevacizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm III (PLD, bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab)
D: Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Arm Label: Chemotherapy + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: liposomal doxorubicin, Drug: paclitaxel, Drug: topotecan | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab | Intervention Type: DRUG; Name: topotecan; Assigned to Arm(s): Chemotherapy, Chemotherapy + Bevacizumab

Answer: B